BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Wednesday, March 25, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Aug. 27, 2014
View Archived Issues
Ebola virus evades the STAT1-mediated immune response
Read More
Novel EZH2 inhibitors for diffuse large B-cell lymphoma identified at Pfizer
Read More
Isis Pharmaceuticals designs new huntingtin ASOs
Read More
Novartis divulges new anti-IL-17A MAbs
Read More
German researchers disclose new MAGE A1-recognizing constructs
Read More
Discovery of antibacterial compounds with promising activity against Gram-positive pathogens
Read More
Novel LXR agonists for the treatment of lipoprotein disorders
Read More
INSERM reports new polypeptides for mitochondrial disorders
Read More
Swedish group patents new deuterated catecholamine derivatives
Read More
DMC recommends initiation of Ruthigen's phase I/II study of RUT-58-60
Read More
Patrys plans phase Ib/II study of PAT-SM6 with carfilzomib in multiple myeloma
Read More
Pfizer and Merck & Co. to evaluate combination of pembrolizumab and crizotinib
Read More
Alkermes initiates phase I trial of the opioid modulator ALKS-7106
Read More
NIH supports Sorrento Therapeutics' development of immunotherapy for IPF
Read More
BeiGene moves BTK inhibitor BGB-3111 into the clinic
Read More
FDA approves Promacta for severe aplastic anemia
Read More
Identification of TLR agonists as novel markers for SSc
Read More
Innate Pharma's IPH-4102 receives E.U. orphan drug status for cutaneous T-cell lymphoma
Read More
EMA accepts for review Cubist's MAA for ceftolozane/tazobactam
Read More
Vivolux plans phase I study of VLX-600 for refractory advanced solid tumors
Read More
Empagliflozin launched in the U.S. for type 2 diabetes
Read More
Adocia launches phase III study of BioChaperone PDGF-BB in diabetic foot ulcers
Read More
